Apoaequorin and memory
What 2 graded rows on apoaequorin agree on for memory, and where they differ. Counted side by side, never averaged.
Consensus finder Rows from the Apoaequorin page, reviewed Oct 21, 2026 How it decides
What the rows agree on
Each block and row is one graded row from the Apoaequorin page, with its PubMed record.
Your question
Apoaequorin and memory
2 rows · 248 peopleSplit. 1 row found no difference and 1 had mixed results.
- DGrade D× 1
- ∅No effect× 1
- Rows
- 2
- Trials
- 2
- People
- 248
What the rows share
From the rowsThe best-graded row, grade D, is a randomized trial of 218 people (2016) and reported mixed results. 1 row is graded No effect, our grade for adequately powered trials that found no effect.
The rows run from 30 to 218 people, published from 2016 to 2024: 2 single studies.
The rows
1 no difference · 1 mixed- ∅No effectCognitive screening scores (AMTS, SMMSE) · No difference
Open-label trial · n 30 · 2024 · People with subjective cognitive decline (15 per group)
Product label dose (not stated in the abstract) · 90 days
The Prevagen group showed no statistically significant change in either screening score from baseline; the comparison product group improved.
Row on the Apoaequorin page · PubMed 39316546 (opens PubMed)
- DGrade DVerbal learning and delayed recall (CogState tasks) · Mixed
RCT · n 218 · 2016 · Community-dwelling adults aged 40–91 with self-reported memory concerns (Madison Memory Study)
10 mg/day · 90 days
The published paper reports significant improvement in verbal learning and recall in the apoaequorin group. The 2017 FTC and New York complaint alleged the study found no significant difference from placebo on any of its nine computerized tasks for the whole sample, and that positive findings came from more than 30 post hoc subgroup analyses.
Row on the Apoaequorin page · PubMed 26878676 (opens PubMed)